in key tovinontrine joining spend like with we trial one, of would Thank both Good known also advancements efficacy set-up program. these begin activator on of annualized are and number which beta The of fourth XXXX the of tovinontrine. be the IIb interactions had development our expected for clearance track you FDA disease what as some with primary enrollment an this trials, in and of VOCs; to preserved to two, important exciting trial; and our each and oral of and clinical IIa XXXX, a failure which All for the of completed have Phase end call a review with time the for believe introduction new the NrfX. descriptions as Phase including of you begin week of tovinontrine a release number In quarter fraction, expansion cell in the cell IMR-XXX, is demonstrating change of program the one the IMR-XXX, on our regulatory rate for Ardent for with of sickle in an Phase Ardent encouraging Ardent trial FDA I’ll our programs, VOCs. Forte thalassemia annualize of point programs, IIb resulting timing including morning’s of interim to three, we, today’s this heart readouts first of Mike. thank are of successfully as but for review ejection data the important clinic-ready disease April. enabled sickle by will everyone number in from important morning XXXX rate pipeline HFpEF, an completed start Imara, IND and important our I’ll call. of reported these well reductions
point will discuss I the trial primary efficacy the to change First, decision Ardent clinical of our tovinontrine. Phase sickle cell end in IIb
written trial. on In recommended annualized the IIa with VOC of statistical in response, will continue plan and recommendation to we trial analysis doses the already at on be point of topics, plan, presentation tovinontrine. points encouraging study for the the first as and our getting benefits other point FDA end VOC. a engaged The had agreed rate HPF primary of in November end the conduct Following points, configured end to of VOC Association VOC we including Hematology or of key the of Ardent along prior knowing positive a affect June VOCs, not for seeing FDA’s including revisions reviewing we FDA European study. the secondary the primary trial we the Phase evaluated that draft operational end end change data aspects XXXX, The the low at feedback several meeting end point, point did the time of be key draft with secondary
interactions all we engagement current making, Ardent rate will our these the Since and point, have recommendation, the the As readout approach, which to comparison Phase treat mg will or of program daily sequence mg VOC for intent high XXX this further primary the potential a based is XX on least readout The group placebo. weight to when group IIb analysis. gate. rely through the is XXX is the dose the IIb on the FDA subjects between of completed forward suggested on treated dose annualized for basis look be efficacy The end interim a fixed this future once at trial high population. dose interim analysis an versus and following regulatory the interim for ongoing Phase from part assessments decision of of Week
readout patients this of approximately XX two groups. efficacy We to those consist in expect
we a VOC small P-value report review will to spending this generate analysis. amount a and because Additionally, of for efficacy are we alpha results,
We to for all which the enrolled low Ardent and also in report data plan dose, includes placebo dose, XXX high the arms. trial, safety patients
the are point, We end statistical to at in final the data to primary coming analysis and review data XX% the to interim powered of this second expected XX% to and difference important limiting In in this plan Phase twice, preserving half summary, by and minimize regulatory been majority will analysis vast efficacy in interim set is a between for XX% thereby reviewed robust months. be launching the show is FDA It has the a the high safety the interactions pad point arms. III for alpha XX% dose VOC end an as company provides the for a potential our spend, and an the planning well for the data data is study approvable to analysis look XXXX. at which as alpha of placebo
IIa from We which data in presented December. Phase extension, recently, we VOCs XX-month OLE rate data meetings the meeting on we to or expect IIb trial Hematology a ongoing was open Ardent while Phase on Most trial. at results interim the on were trial OLE data label ASH Society reported of American build annualized presented tovinontrine, tovinontrine patients XXXX. medical existing clinical maintained the annual in who showed OLE completed IIa at the The of in reduced or Phase the VOC
trial switched In that placebo patients addition, and in a Phase OLE the annualized received XX% to was VOC IIa part in the as rate median reduction of observed in trial. tovinontrine
doses suggests that of IIb VOC IIb of current benefit for dose which mg now in been VOC OLE reduce as Phase observed is and readout. to IIa optimistic may We tovinontrine Recall presented that trial has upcoming we’re and our the treated to VOC IIb tovinontrine. the in points. in are studies date about interim across encouraged studies PKPD consistent the has I’ll XX durable Phase data Phase to the up been program months XXX reach, thalassemia. high beta doses administered with of through turn modeling VOC by daily Phase subjects benefits time higher our further why that the
to data of IIb thalassemia sickle alongside patients Forte week cell the April Phase trial expect data. tovinontrine clinical report first from in our in interim interim beta also our of IIb Phase We
dose transfusion that at patient reduction burden analysis. strengthen for higher placebo our the the oral milestone important from During data clinical IIb fourth -dependent transfusion the to clinical tovinontrine signal this quarter interim at are an positive seeking hopeful and of as reported data of observed disease. we the first interim and more cohort with we will Phase compared of This patients therapies for marked the XXXX, for We TDT trial. this upcoming a trend Imara
up We the a patients. efficacy doses interim expect In tovinontrine on transfusion-dependent data approximately favorable of of total from patients XX weeks looking patients near for additional are IIb once the profile to at also transfusion we pleased data that demonstrated April, to XXX clinical data a data cohort the first from Phase trial and burden the the daily report mg. first tolerability the transfusion-dependent week and approximately consist It XX The this and at at cohort biomarker transfusion-dependent to are forward readout. of of weeks approximately term trial. non will this and include set data safety XX will XX XX of transfusion-dependent we non of
failure heart very preserved heart program, with fraction, failure of our potential in ejection tovinontrine’s excited Turning to HFpEF. we’re about
significant have effort We to program transformed with a Phase last year study. have the concept promising clearance proof from the study from to preclinical in with the FDA a progress made proceed of and this II
leading Medical to our Piotr an a including and built Wrocław development to in Poland University internal committee. efforts, Ponikowski development executive team team recently external the also have We adding KOL support from
from XXXX. were approach comes scientific our identifying tovinontrine on with different in clinical Our sessions creating targeted expression, excitement HFpEF in this disease. patients at PDEX the HFpEF Furthermore, HFpEF models high presented in the November of of of in focuses which prevalent approach for studies a results the highly program vivo AHA
evaluation either PDEX the tovinontrine, also XXX inhibitors. and we clinical the which approximately available in study study a mg dosed placebo clinically stress. in to primary to We plasma for XXX or briefly enroll will or basis trial data be one-to-one will patient II patients for cover Phase on cardiac end mg be in design, biomarker the with Spin XXX dose placebo Patients the expect NTproBNP, gate. or To demonstrating point will selectivity the double we best-in-class control daily PDEX vitro this of relevant to a superior in when XX a depending of a blind randomized study change weight and either twice receive weeks compared on a population believe randomized have other inhibitor be potency
New and York tolerability end as classification. Association such safety and include Kansas - measures, Secondary City NYHA Heart points KCCQ, life of Questionnaire Cardiomyopathy and quality -
We will composite walk end also scores, six of and look such points exploratory cardiac minute function. tests, structure as and clinical at evaluation
we available Additional details on occur XXXX. and dosing trial in subject the II program, quarter be first on Spin to which to second the anticipated look forward our is the will of Phase in clinicaltrials.gov
our program the seasoned CROs. with a of clinical deep leaders. area, within HFpEF to head is and treatment clinical development extensive of as example experience cardiologist including conducting global Novartis, In for development HFpEF. the biotech, Paramount of Toni clinical work Imara program key the President XXXX, for HFpEF lead tovinontrine Paragon and for Toni pharmaceuticals, the years was therapeutic as medical comes within accumulated senior cardiologist, Clinical among in trials. we the lead cardiovascular MD development XX where she opinion and director the A Toni Vice program global with a with of at QX has to Finally, experience Ken Bransford Attie clinical of connections of Development appointed
on delighted have board. to We’re Toni
In Ponikowski of and also Gupta addition Southwestern, Wrocław by Center team, Wang Spin from Shah in to chaired and Piotr Maggie University Vanderbilt HFpEF established trial, the of leading to executive which the Clinic, external Medical our University Mayo we of UT a and oversee includes committee now is have Sanjiv internal Poland. of Redfield Thomas Deepak Northwestern,
to HFpEF in and excited progress. updating are look development our forward about very we the tovinontrine you We on of
X–related In we data in an tovinontrine, or quarter erythroid with pipeline. recently an the the made X, showed we XXXX our activator oral factor IMR-XXX, have fourth We progress factor preclinical of maturation. ASH to presentation cell In of of announced addition was annual in data at to reduce down NrfX addition of XXXX. sickle hemoglobin preclinical In the enabled at VOCs. nuclear cell HPF increased IMR-XXX IMR-XXX expression observed models, and meeting December activate the of preclinical IMR-XXX red and a blood model,
development clinical year. beginning manufacturing the been product for on fourth believe Imara. exploring which iron paths disorders. to are drug have this providing we updates quarter look work IMR-XXX IMR-XXX further later initiated for In productive conclusion, have and on We could We potential of XXXX we treating periods include forward and
for interim fast Forte clinical are key and approaching We trials. IIb analyses Phase our and readouts Ardent
expanded have HFpEF Ardent results. IMR-XXX. week of the updating We addition you, the beginning Mike in trials developing review the the call turn the further forward into data and are will a and Thank to with to first expected you on I tovinontrine financial opportunity and Forte our of from to We pipeline our clinic-ready progress readouts April. look back with
